Karyopharm Therapeutics Inc [KPTI] stock is trading at $4.86, up 24.94%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The KPTI shares have gain 16.27% over the last week, with a monthly amount glided 12.24%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Karyopharm Therapeutics Inc [NASDAQ: KPTI] stock has seen the most recent analyst activity on July 16, 2025, when H.C. Wainwright downgraded its rating to a Neutral. On January 19, 2023, Piper Sandler initiated with a Overweight rating and assigned a price target of $8 on the stock. RBC Capital Mkts upgraded its rating to a Outperform and increased its price target to $10 on November 04, 2022. JP Morgan upgraded its rating to a Neutral but $8 remained the price target by the analyst firm on February 09, 2022. In a note dated August 06, 2021, SVB Leerink downgraded an Mkt Perform rating on this stock but restated the target price of $6.
Karyopharm Therapeutics Inc [KPTI] stock has fluctuated between $3.51 and $16.95 over the past year. Currently, Wall Street analysts expect the stock to reach $7.33 within the next 12 months. Karyopharm Therapeutics Inc [NASDAQ: KPTI] shares were valued at $4.86 at the most recent close of the market. An investor can expect a potential return of 50.82% based on the average KPTI price forecast.
Analyzing the KPTI fundamentals
Karyopharm Therapeutics Inc [NASDAQ:KPTI] reported sales of 142.13M for the trailing twelve months, which represents a drop of -9.39%. Gross Profit Margin for this corporation currently stands at 0.96% with Operating Profit Margin at -0.84%, Pretax Profit Margin comes in at -0.44%, and Net Profit Margin reading is -0.44%. To continue investigating profitability, this company’s Return on Assets is posted at -0.49, Equity is 0.37 and Total Capital is -3.19. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -0.44.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 4.17 points at the first support level, and at 3.47 for the second support level. However, for the 1st resistance point, the stock is sitting at 5.23, and for the 2nd resistance point, it is at 5.59.
Ratios To Look Out For
For context, Karyopharm Therapeutics Inc’s Current Ratio is 1.33. As well, the Quick Ratio is 1.28, while the Cash Ratio is 0.43. Considering the valuation of this stock, the price to sales ratio is 0.30.
Transactions by insiders
Recent insider trading involved Abate Kristin, Chief Accounting Officer, that happened on Jul 22 ’25 when 238.0 shares were sold. President and CEO, Paulson Richard A. completed a deal on May 06 ’25 to sell 236.0 shares. Meanwhile, EVP & Chief Medical Officer Rangwala Reshma sold 419.0 shares on Apr 23 ’25.
